• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Adult moyamoya angiopathy in Bourgogne-Franche-Comt é: Epidemiology, diagnosis and management.
CONCLUSION: MMA remains a rare cerebrovascular disease in Europe and requires multidisciplinary care. Epidemiological analysis showed differences with the Asian population, especially the predominance of ischemic forms in adults. PMID: 30447881 [PubMed - as supplied by publisher]
Source: Revue Neurologique - November 19, 2018 Category: Neurology Tags: Rev Neurol (Paris) Source Type: research

Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS
ConclusionConsistent with results from clinical trials and other observational studies, dabigatran and rivaroxaban were at least as effective and safer than VKAs for the prevention of thromboembolic events in NVAF over 1 year in the French population.Study registrationEuropean Medicines Agency EUPAS 13017 (www.encepp.eu) Clinicaltrials.gov id NCT02785354.
Source: American Journal of Cardiovascular Drugs - June 28, 2019 Category: Cardiology Source Type: research

Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
CONCLUSION: The COMPASS therapeutic strategy in France appears to be applicable to more than half of CAD or PAD patients. This population appears at high residual risk of atherothrombotic events, and patients with polyvascular disease experienced the highest rate of events. PMID: 32778388 [PubMed - as supplied by publisher]
Source: Annales de Cardiologie et d'Angeiologie - August 6, 2020 Category: Cardiology Authors: Darmon A, Elbez Y, Bhatt DL, Abtan J, Mas JL, Cacoub P, Montalescot G, Billaut-Laden I, Ducrocq G, Steg PG Tags: Ann Cardiol Angeiol (Paris) Source Type: research

A Multicenter Preliminary Study of Cangrelor following Thrombectomy Failure for Refractory Proximal Intracranial Occlusions INTERVENTIONAL
CONCLUSIONS: Cangrelor seems to be as safe as glycoprotein IIb/IIIa inhibitors for managing refractory intracranial occlusion and leads to satisfactory brain reperfusion. Cangrelor is a promising agent in this setting, and additional studies are warranted to confirm our findings.
Source: American Journal of Neuroradiology - August 11, 2021 Category: Radiology Authors: Marnat, G., Delvoye, F., Finitsis, S., Lapergue, B., Gariel, F., Consoli, A., Desilles, J.- P., Mazighi, M., Dargazanli, C., Bourcier, R., Darcourt, J., Chalumeau, V., Elhorany, M., Clarencon, F., Richard, S., Gory, B., Sibon, I., on behalf of the ETIS In Tags: INTERVENTIONAL Source Type: research

As some hail new antibody treatment for Alzheimer ’s, safety and benefit questions persist
In a packed San Francisco conference room with a celebratory atmosphere, upbeat company representatives and scientists yesterday presented detailed clinical trial data on the first Alzheimer’s treatment shown to clearly, albeit modestly, slow the disease’s normal cognitive decline. The antibody therapy has buoyed a field marked by decades of failures. Now, it appears to be on the cusp of being greenlit by the U.S. Food and Drug Administration (FDA). Yet other researchers warn of potential risks, including brain swelling and brain hemorrhages that were linked to the recently disclosed deaths of two trial participants wh...
Source: Science of Aging Knowledge Environment - December 1, 2022 Category: Geriatrics Source Type: research

E-007 CLEVER: clinical evaluation of WEB 0.017 device in intracranial aneurysms - final results for ruptured and unruptured aneurysm at 12 months
ConclusionThese results show good efficacy and safety results at 12 months month, and no WEB related mortality at 12 months. These data confirm the safety and efficacy of WEB 0.017 use in intracranial aneurysm treatment, unruptured as well as ruptured, and are consistent with the results published up to date.Disclosures L. Spelle: 1; C; Philips. 2; C; Microvention, Stryker, Medtronic, Balt, Phenox. C. Cognard: 2; C; Stryker, Medtronic, Mivi, Cerenovus, Microvention. I. Szikora: 2; C; Stryker, Cerenovus, Medtronic, Microvention, Brainomix. F. Wodarg: 2; C; Microvention, Stryker, Cerus Endovascular, Balt, Johnson & Johns...
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: Spelle, L., Cognard, C., Szikora, I., Wodarg, F., Costalat, V., Herbreteau, D., Fischer, S., Möhlenbruch, M., Papagiannaki, C., Klisch, J., Rautio, R., Berlis, A., Downer, J., Bester, M., Velasco, S., Liebig, T., Byrne, J., Pierot, L. Tags: SNIS 20th annual meeting electronic poster abstracts Source Type: research

Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people.
The objectives of AF treatment in the elderly are to prevent AF complications, particularly stroke, and improve quality of life. Specific precautions for treatment must be taken because of the co-morbidities and age-related changes in pharmacokinetics or pharmacodynamics. Preventing AF complications relies mainly on anticoagulant therapy. Anticoagulants are recommended in patients with AF aged 75 years or above after assessing the bleeding risk using the HEMORR2HAGES or HAS-BLED scores. Novel oral anticoagulants (NOACs) are promising treatments, especially due to a lower risk of intracerebral haemorrhage. However, their pr...
Source: Archives of Cardiovascular Diseases - May 1, 2013 Category: Cardiology Authors: Hanon O, Assayag P, Belmin J, Collet JP, Emeriau JP, Fauchier L, Forette F, Friocourt P, Gentric A, Leclercq C, Komajda M, Le Heuzey JY Tags: Arch Cardiovasc Dis Source Type: research

Impact of resident and fellow changeovers on patient outcomes: a nationwide cross-sectional study
ConclusionOur findings provide some reassurance regarding cohort changeover and mortality even if they suggest a loss of efficiency in some cases.
Source: The European Journal of Public Health - May 25, 2017 Category: General Medicine Source Type: research

Mechanical thrombectomy of M2 occlusions with distal access catheters using ADAPT
Conclusion: DACs can safely be used for mechanical thrombectomy of acute M2 occlusions by the ADAPT approach. Their use alone can be a high efficacious treatment of distal intracranial thromboembolic occlusions.
Source: Journal of Neuroradiology - February 14, 2019 Category: Radiology Source Type: research

Early Prophylactic Hypothermia for Patients With Severe Traumatic Injury: Premature to Close the Case
This study demonstrates that there is no role for the initiation of hypothermia during the acute phase of TBI (1, 2). However, it would be damaging to abandon the concept prematurely. Inflammation Also Paves the Way to Tissue Repair As soon as trauma occurs, the inflammatory cascade begins to take place. The deleterious role of inflammation in the secondary injury response is well-documented, hence the rationale to attempt early prophylactic hypothermia in TBI. However, inflammation also initiates tissue repair and regeneration (3–6). We now know that the secondary injury response accompanies the regenerating and...
Source: Frontiers in Neurology - April 8, 2019 Category: Neurology Source Type: research

Determinants of Antithrombotic Treatment for Atrial Fibrillation in Octogenarians: Results of the OCTOFA Study
ConclusionsMost private-practice cardiologists prescribe anticoagulant treatment according to current guidelines in elderly atrial fibrillation patients. Non-vitamin K antagonist oral anticoagulants represent a significant proportion of prescriptions.
Source: Clinical Drug Investigation - June 9, 2019 Category: Drugs & Pharmacology Source Type: research

Impact of the physical activity on the phenotype of circulating monocytes and the biological characteristics of the carotid plaque
Atherosclerosis is accompanied by a low-grade inflammation which mobilizes the classical, intermediate and non-classical circulating monocytes. It was shown that an accumulation of leucocytes supports the development of intraplaque hemorrhage (IPH), making the plaque vulnerable, exposed to rupture and thrombosis. Moreover, the elevation of the rate of intermediate monocytes is associated with an increase in cardiovascular mortality and ischemic stroke. The benefit of endarterectomy (CE) remains discussed in the patients without stroke.
Source: Annals of Vascular Surgery - September 24, 2019 Category: Surgery Authors: Mathilde Mura, Mich èle Weiss, Nellie Della Schiava, Marine Bordet, Patrick Lermusiaux, Antoine Millon, Vincent Pialoux Tags: Abstracts Presented to the French Society for Vascular and Endovascular Surgery Source Type: research

Initial Experience Performing Mechanical Thrombectomy With the CatchView Mini Device for Distal M2 Segment Middle Cerebral Artery Occlusions
Conclusions: The present analysis demonstrates a low risk profile and high recanalization success for patients with distal M2 occlusions treated with the CVM device.
Source: Frontiers in Neurology - September 14, 2021 Category: Neurology Source Type: research

O-003 CLEVER: clinical evaluation of WEB 17 device in intracranial aneurysms. safety results for ruptured and unruptured aneurysm at 30 days
ConclusionThese results show good safety profile at 1 month, with low rate of neurological or neurovascular event with permanent deficit and no mortality at 30 days. These data confirm the safety of WEB use in intracranial aneurysm treatment, unruptured as well as ruptured, and are consistent with the results published up to date.Disclosures L. Spelle: 2; C; Microvention, Medtronic, Phenox, Stryker, Balt. C. Cognard: None. I. Szikora: None. V. Costalat: None. F. Wodarg: None. D. Herbreteau: None. S. Fischer: None. M. Möhlenbruch: None. C. Papagiannaki: None. J. Klisch: None. R. Rautio: None. J. Numminen: None. A. B...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Spelle, L., Cognard, C., Szikora, I., Costalat, V., Wodarg, F., Herbreteau, D., Fischer, S., Möhlenbruch, M., Papagiannaki, C., Klisch, J., Rautio, R., Numminen, J., Berlis, A., Downer, J., Bester, M., Velasco, S., Liebig, T., Byrne, J., Pierot, L Tags: SNIS 19th annual meeting oral abstracts Source Type: research

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study
CONCLUSION: Among patients with AF, apixaban use was associated with lower risk for GIB and similar rates of ischemic stroke or systemic embolism, ICH, and all-cause mortality compared with dabigatran, edoxaban, and rivaroxaban. This finding was consistent for patients aged 80 years or older and those with chronic kidney disease, who are often underrepresented in clinical trials.PRIMARY FUNDING SOURCE: None.PMID:36315950 | DOI:10.7326/M22-0511
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Wallis C Y Lau Carmen Olga Torre Kenneth K C Man Henry Morgan Stewart Sarah Seager Mui Van Zandt Christian Reich Jing Li Jack Brewster Gregory Y H Lip Aroon D Hingorani Li Wei Ian C K Wong Source Type: research

Pages: 1  2  3  4  5  6  7